CytoTools AG
XETRA:T5O
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
N/A
N/A
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one T5O stock under the Base Case scenario is 152 EUR. Compared to the current market price of 101.26 EUR, CytoTools AG is Undervalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
CytoTools AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for T5O cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
CytoTools AG
Balance Sheet Decomposition
CytoTools AG
Current Assets | 1.2m |
Cash & Short-Term Investments | 1.1m |
Receivables | 50.5k |
Other Current Assets | 45.2k |
Non-Current Assets | 20.2m |
Long-Term Investments | 20.2m |
PP&E | 660 |
Other Non-Current Assets | 2.7k |
Current Liabilities | 59.6k |
Accounts Payable | 47.9k |
Other Current Liabilities | 11.7k |
Non-Current Liabilities | 170.8k |
Other Non-Current Liabilities | 170.8k |
Earnings Waterfall
CytoTools AG
Revenue
|
20.5k
EUR
|
Operating Expenses
|
-706k
EUR
|
Operating Income
|
-685.5k
EUR
|
Other Expenses
|
24.8k
EUR
|
Net Income
|
-660.7k
EUR
|
Free Cash Flow Analysis
CytoTools AG
EUR | |
Free Cash Flow | EUR |
T5O Profitability Score
Profitability Due Diligence
CytoTools AG's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
CytoTools AG's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
T5O Solvency Score
Solvency Due Diligence
CytoTools AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
CytoTools AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
T5O Price Targets Summary
CytoTools AG
According to Wall Street analysts, the average 1-year price target for T5O is 25.93 EUR with a low forecast of 25.68 EUR and a high forecast of 26.7 EUR.
Dividends
Current shareholder yield for T5O is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
CytoTools AG is a biotechnology company, which engages in the research and development of therapies to treat cause of diseases. The company is headquartered in Darmstadt, Hessen and currently employs 1 full-time employees. The company went IPO on 2007-05-18. The firm holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. CytoTools AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections, and pre-clinical stage CardioClean for the treatment of restenosis, diabetis and carotis-stenosis.
Contact
IPO
Employees
Officers
The intrinsic value of one T5O stock under the Base Case scenario is 152 EUR.
Compared to the current market price of 101.26 EUR, CytoTools AG is Undervalued by 33%.